Lali G. Ambatiello
Lali G. Ambatiello has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Irina Evgenievna Chazova
E.I. Chazov National Medical Research Center Of Cardiology
8 shared publications - Ekaterina V. Smolyakova
Federal State Budgetary Educational Institution of Higher Education “Russian University of Medicine” of the Ministry of Healthcare of the Russian Federation, 127006 Moscow, Russia
4 shared publications - Kirill Alekseevich Zykov
Research Institute for Pulmonology of the Federal Medical Biological Agency; Russian University of Medicine (ROSUNIMED)
4 shared publications - A. A. Klimova
E.I. Chazov National Medical Research Center Of Cardiology
3 shared publications Амбатьелло Лали Гурамовна
ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России
3 shared publications- Anna V. Aksenova
Chazov National Medical Research Center of Cardiology
2 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (3) , 189-195
Renin-angiotensin-aldosterone system blockers in the treatment of patients with cardiovascular diseases combined with bronchial obstruction diseases: a review
The renin-angiotensin-aldosterone system (RAAS) is the main target of pharmacological agents used to achieve blood pressure reduction as well as cardio- and nephroprotection in patients with cardiovascular diseases (CVD). However, the use of drugs from this group, primarily angiotensin-converting enzyme inhibitors (ACE inhibitors), may lead to the development of adverse events (AEs) in patients with obstructive lung diseases (OLD). ACE inhibitors and angiotensin II receptor blockers (ARBs) have comparable efficacy in the treatment of CVD. In the event of AEs, patients receiving ACE inhibitors for arterial hypertension may be switched to ARBs. However, for the treatment of chronic heart failure with reduced ejection fraction, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction, ACE inhibitors are recommended as first-line therapy; the benefits of ARBs in these conditions have not been proven. Mineralocorticoid receptor antagonists (MRAs) are also frequently prescribed to patients with CVD as part of combination therapy. In addition to their proven efficacy in the treatment of CVD, spironolactone and eplerenone have demonstrated antifibrotic and anti-inflammatory effects in a number of studies, including effects in lung tissue, as well as the ability to influence the progressive course of fibrotic diseases. This class of drugs is being intensively studied. In the United States, Europe, and Japan, new agents from the subclass of nonsteroidal MRAs have been approved. Currently, investigation of the potential of MRAs is highly promising for patients with coexisting CVD and OLD, given the potential of these drugs to affect inflammation and fibrosis in lung tissue. Thus, this review is devoted to the analysis of the efficacy and safety of RAAS-targeting drugs in patients with CVD and OLD, the causes of adverse events, and proposes management strategies for their occurrence and possible correction.
- 17 March 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (3) , 189-195
Open AccessRenin-angiotensin-aldosterone system blockers in the treatment of patients with cardiovascular diseases combined with bronchial obstruction diseases: a review
The renin-angiotensin-aldosterone system (RAAS) is the main target of pharmacological agents used to achieve blood pressure reduction as well as cardio- and nephroprotection in patients with cardiovascular diseases (CVD). However, the use of drugs from this group, primarily angiotensin-converting enzyme inhibitors (ACE inhibitors), may lead to the development of adverse events (AEs) in patients with obstructive lung diseases (OLD). ACE inhibitors and angiotensin II receptor blockers (ARBs) have comparable efficacy in the treatment of CVD. In the event of AEs, patients receiving ACE inhibitors for arterial hypertension may be switched to ARBs. However, for the treatment of chronic heart failure with reduced ejection fraction, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction, ACE inhibitors are recommended as first-line therapy; the benefits of ARBs in these conditions have not been proven. Mineralocorticoid receptor antagonists (MRAs) are also frequently prescribed to patients with CVD as part of combination therapy. In addition to their proven efficacy in the treatment of CVD, spironolactone and eplerenone have demonstrated antifibrotic and anti-inflammatory effects in a number of studies, including effects in lung tissue, as well as the ability to influence the progressive course of fibrotic diseases. This class of drugs is being intensively studied. In the United States, Europe, and Japan, new agents from the subclass of nonsteroidal MRAs have been approved. Currently, investigation of the potential of MRAs is highly promising for patients with coexisting CVD and OLD, given the potential of these drugs to affect inflammation and fibrosis in lung tissue. Thus, this review is devoted to the analysis of the efficacy and safety of RAAS-targeting drugs in patients with CVD and OLD, the causes of adverse events, and proposes management strategies for their occurrence and possible correction.
- Open Access
- 29 October 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (3) , 5-18
Medical Society of Hypertension. Use of beta-blockers in patients with hypertension
This Russian Medical Society for Arterial Hypertension expert consensus describes the beta-blockers's role in treatment strategy of the arterial hypertension combined with cardiovascular diseases and other comorbidities, which may be more frequent in hypertensive patients than in patients with normal blood pressure level.
- 29 October 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (3) , 5-18
Open AccessMedical Society of Hypertension. Use of beta-blockers in patients with hypertension
This Russian Medical Society for Arterial Hypertension expert consensus describes the beta-blockers's role in treatment strategy of the arterial hypertension combined with cardiovascular diseases and other comorbidities, which may be more frequent in hypertensive patients than in patients with normal blood pressure level.
- Open Access
- 28 March 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (1) , 35-42
Possibilities of using a modified questionnaire in patients with broncho-obstructive pathology admitted to a specialized cardiology hospital
The aim of this study is to evaluate the effectiveness of the modified DCSI questionnaire (Dyspnea, Cough, Smoking, chronic recurrent respiratory Infections) developed by us to identify broncho-obstructive diseases (BOD) (COPD and bronchial asthma) in patients with cardiovascular diseases (CvD) and to compare the indicators of spirometric research in different groups of cardiac patients formed on its basis.Materials and methods. The sample consisted of patients over 18 years of age with arterial hypertension (AH), including chronic heart failure (CHF), coronary heart disease (CHD), heart rhythm disturbances (HRD), admitted to the National Medical Research Center of Cardiology over a two-year period. The sample consisted of 1000 cardiology patients, including 137 patients with comorbid COPD and bronchial asthma diagnosed before participation in the study, 71 patients with comorbid COPD and bronchial asthma diagnosed for the first time during the study, 792 cardiology patients without comorbid COPD and bronchial asthma. All cardiac patients filled out the modified DCSI questionnaire in the emergency room. All cardiac patients underwent pulmonary examination, which included computer spirometry (including bronchodilator test) in accordance with the recommendations of the European Respiratory Society. The main spirometric parameters were recorded: Gaensler index (modified Tiffeneau index, FEv1/FvC) (normal >70%), FEv1% (normal >80%) and FvC% (normal >80%). Patients with deviations detected in spirometry data were consulted by a pulmonologist.Results. All cardiac patients with COPD and bronchial asthma (137 patients with previously diagnosed comorbid COPD and bronchial asthma and 71 patients with newly diagnosed comorbid COPD and bronchial asthma during the study) had ≥2 points on the DCSI questionnaire. Cardiac patients without comorbid COPD and bronchial asthma had Conclusions. The DCSI questionnaire developed by us for screening risk factors and symptoms of broncho-obstructive pathology in patients admitted to a cardiology hospital effectively excludes comorbid COPD and bronchial asthma at <2 points (0-1) and identifies previously undiagnosed comorbid COPD and bronchial asthma at 4 points. At 2 or 3 points, the diagnosis of COPD and bronchial asthma is potentially probable, and routine computer spirometry is recommended for a cardiac patient. Cardiology patients with newly diagnosed comorbid COPD and bronchial asthma have lower spirometric parameters (FEv1%, FvC%, Gaensler index) than patients with previously diagnosed comorbid COPD and bronchial asthma.
- 28 March 2025
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 22 (1) , 35-42
Open AccessPossibilities of using a modified questionnaire in patients with broncho-obstructive pathology admitted to a specialized cardiology hospital
The aim of this study is to evaluate the effectiveness of the modified DCSI questionnaire (Dyspnea, Cough, Smoking, chronic recurrent respiratory Infections) developed by us to identify broncho-obstructive diseases (BOD) (COPD and bronchial asthma) in patients with cardiovascular diseases (CvD) and to compare the indicators of spirometric research in different groups of cardiac patients formed on its basis.Materials and methods. The sample consisted of patients over 18 years of age with arterial hypertension (AH), including chronic heart failure (CHF), coronary heart disease (CHD), heart rhythm disturbances (HRD), admitted to the National Medical Research Center of Cardiology over a two-year period. The sample consisted of 1000 cardiology patients, including 137 patients with comorbid COPD and bronchial asthma diagnosed before participation in the study, 71 patients with comorbid COPD and bronchial asthma diagnosed for the first time during the study, 792 cardiology patients without comorbid COPD and bronchial asthma. All cardiac patients filled out the modified DCSI questionnaire in the emergency room. All cardiac patients underwent pulmonary examination, which included computer spirometry (including bronchodilator test) in accordance with the recommendations of the European Respiratory Society. The main spirometric parameters were recorded: Gaensler index (modified Tiffeneau index, FEv1/FvC) (normal >70%), FEv1% (normal >80%) and FvC% (normal >80%). Patients with deviations detected in spirometry data were consulted by a pulmonologist.Results. All cardiac patients with COPD and bronchial asthma (137 patients with previously diagnosed comorbid COPD and bronchial asthma and 71 patients with newly diagnosed comorbid COPD and bronchial asthma during the study) had ≥2 points on the DCSI questionnaire. Cardiac patients without comorbid COPD and bronchial asthma had Conclusions. The DCSI questionnaire developed by us for screening risk factors and symptoms of broncho-obstructive pathology in patients admitted to a cardiology hospital effectively excludes comorbid COPD and bronchial asthma at <2 points (0-1) and identifies previously undiagnosed comorbid COPD and bronchial asthma at 4 points. At 2 or 3 points, the diagnosis of COPD and bronchial asthma is potentially probable, and routine computer spirometry is recommended for a cardiac patient. Cardiology patients with newly diagnosed comorbid COPD and bronchial asthma have lower spirometric parameters (FEv1%, FvC%, Gaensler index) than patients with previously diagnosed comorbid COPD and bronchial asthma.
- Open Access
- 25 December 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (4) , 5-110
Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.
- 25 December 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (4) , 5-110
Open AccessClinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024)
The сlinical guidelines present the main approaches to the management of patients with arterial hypertension (aH) using the principles of evidence-based medicine. The guidelines include sections containing expanded and updated information on the main aspects of diagnosis, treatment, prevention methods and follow-up patients with hypertension, taking into account the phenotypes of disease and various clinical situations, as well as secondary forms of hypertension of various origins.
- Open Access
- 27 October 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (3) , 7-15
Stress-induced arterial hypertension: search for predictors
Background. Despite the existence of a clear cause-and-effect relationship between job strain and hypertension, there are still no clear criteria for defining stress-induced arterial hypertension (SIAH). Objective. Search for SIAH criteria, in particular predictors of hypertension in the workplace. Materials and methods. The study included volunteers experiencing stress in the workplace and not having hypertension. Before the start of the working day and at the end of the working day, the subject was surveyed, given questionnaires (Ch. D. Spielberg scale, Montgomery-Asberg MADRS scale, A. M. Vein scale, hospital anxiety and depression scale HADS), blood pressure and resting heart rate were measured, fasting blood was taken to determine the values of ACTH, TSH, T4, insulin, cortisol. All patients underwent ABPM on a working day and a day off. Results. According to ABPM (n=52), no signs of masked hypertension were detected, however, significant differences between workdays and weekends in the levels of maximum SBP and DBP during the daytime were noteworthy. In the group with maximum SBP>140 mm Hg during the daytime (SIAH, n = 34), on a workday there was an increase in the time index for SBP>30% (24 hours and day), characteristic of hypertension, and for DBP (24 hours and day), characteristic of borderline (possible) hypertension, the average DBP values during the day and at night were at the upper limit of the norm, which was significantly different from the Normotonic group (n = 19). On a weekday, the SIAH group also had significantly increased SBP (24 hours, day) and DBP (24 hours, day and night) indexes versus Normotonic. For all other indicators except ABPM, the groups were comparable. Conclusions. Taking into account the increase in the time index for SBP and DBP, it can be assumed that, against the background of stressful situations at the workplace, the subjects had short frequent increases in blood pressure, which have not yet led to a significant violation of self-regulation of blood pressure and the development of hypertension. An increase in the maximum values of systolic and/or diastolic blood pressure against the background of an increased time index on a working day are possible predictors of SIAH, in particular hypertension at the workplace.
- 27 October 2024
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 21 (3) , 7-15
Open AccessStress-induced arterial hypertension: search for predictors
Background. Despite the existence of a clear cause-and-effect relationship between job strain and hypertension, there are still no clear criteria for defining stress-induced arterial hypertension (SIAH). Objective. Search for SIAH criteria, in particular predictors of hypertension in the workplace. Materials and methods. The study included volunteers experiencing stress in the workplace and not having hypertension. Before the start of the working day and at the end of the working day, the subject was surveyed, given questionnaires (Ch. D. Spielberg scale, Montgomery-Asberg MADRS scale, A. M. Vein scale, hospital anxiety and depression scale HADS), blood pressure and resting heart rate were measured, fasting blood was taken to determine the values of ACTH, TSH, T4, insulin, cortisol. All patients underwent ABPM on a working day and a day off. Results. According to ABPM (n=52), no signs of masked hypertension were detected, however, significant differences between workdays and weekends in the levels of maximum SBP and DBP during the daytime were noteworthy. In the group with maximum SBP>140 mm Hg during the daytime (SIAH, n = 34), on a workday there was an increase in the time index for SBP>30% (24 hours and day), characteristic of hypertension, and for DBP (24 hours and day), characteristic of borderline (possible) hypertension, the average DBP values during the day and at night were at the upper limit of the norm, which was significantly different from the Normotonic group (n = 19). On a weekday, the SIAH group also had significantly increased SBP (24 hours, day) and DBP (24 hours, day and night) indexes versus Normotonic. For all other indicators except ABPM, the groups were comparable. Conclusions. Taking into account the increase in the time index for SBP and DBP, it can be assumed that, against the background of stressful situations at the workplace, the subjects had short frequent increases in blood pressure, which have not yet led to a significant violation of self-regulation of blood pressure and the development of hypertension. An increase in the maximum values of systolic and/or diastolic blood pressure against the background of an increased time index on a working day are possible predictors of SIAH, in particular hypertension at the workplace.
- Open Access
- 27 March 2023
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 20 (1) , 35-43
The frequency of detection of comorbid broncho-obstructive pathology in patients with arterial hypertension admitted to a specialized cardiological hospital
Objective: To determine the frequency of detection of chronic obstructive pulmonary disease (COPD) and Asthma in patients who are admitted to specialized cardiological hospital with arterial hypertension (AH), including AH with chronic heart failure (CHF), coronary heart disease (CHD), cardiac arrhythmias. Analyze the possibility of early diagnosis and the validity of the modified questionnaire for screening risk factors and symptoms of broncho-obstructive pathology in patients with arterial hypertension.Materials and methods: The sample (n = 1000) consisting of individuals over the age of 18 who continuously arrive for inpatient treatment at the admission department of the National Medical Research Center of Cardiology with arterial hypertension, incl. AH with CHF, IHD and arrhythmias in the period from 2018 to 2019. Active identification of broncho-obstructive pathology among all persons was carried out (history taking, complaints), analysis of medical documents provided by patients (conclusions from outpatient and reference cards of the patient), screening of risk factors and symptoms of broncho-obstructive pathology (a modified questionnaire was used), external respiration function was assessed (computer spirometry), filled out the specialized respiratory questionnaires (CAT, mMRC, ACT).Results: The undiagnosed broncho-obstructive diseases was demonstrated against the background of their high occurrence in patients with hypertension, incl. CHF, coronary artery disease, NRS entering a specialized cardiological hospital. The study established the most likely predictors of airway obstruction in patients with hypertension, which signal the need to assess the function of external respiration (computed spirometry).Conclusions: The development and validation of a modified questionnaire makes it possible to identify specific symptoms and risk factors for bronchoobstructive diseases against the backdrop of their high prevalencre among patients who are admitted to cardiology hospital with arterial hypertension.
- 27 March 2023
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 20 (1) , 35-43
Open AccessThe frequency of detection of comorbid broncho-obstructive pathology in patients with arterial hypertension admitted to a specialized cardiological hospital
Objective: To determine the frequency of detection of chronic obstructive pulmonary disease (COPD) and Asthma in patients who are admitted to specialized cardiological hospital with arterial hypertension (AH), including AH with chronic heart failure (CHF), coronary heart disease (CHD), cardiac arrhythmias. Analyze the possibility of early diagnosis and the validity of the modified questionnaire for screening risk factors and symptoms of broncho-obstructive pathology in patients with arterial hypertension.Materials and methods: The sample (n = 1000) consisting of individuals over the age of 18 who continuously arrive for inpatient treatment at the admission department of the National Medical Research Center of Cardiology with arterial hypertension, incl. AH with CHF, IHD and arrhythmias in the period from 2018 to 2019. Active identification of broncho-obstructive pathology among all persons was carried out (history taking, complaints), analysis of medical documents provided by patients (conclusions from outpatient and reference cards of the patient), screening of risk factors and symptoms of broncho-obstructive pathology (a modified questionnaire was used), external respiration function was assessed (computer spirometry), filled out the specialized respiratory questionnaires (CAT, mMRC, ACT).Results: The undiagnosed broncho-obstructive diseases was demonstrated against the background of their high occurrence in patients with hypertension, incl. CHF, coronary artery disease, NRS entering a specialized cardiological hospital. The study established the most likely predictors of airway obstruction in patients with hypertension, which signal the need to assess the function of external respiration (computed spirometry).Conclusions: The development and validation of a modified questionnaire makes it possible to identify specific symptoms and risk factors for bronchoobstructive diseases against the backdrop of their high prevalencre among patients who are admitted to cardiology hospital with arterial hypertension.
- Open Access
- 12 August 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (7) , 908-913
Stress-induced arterial hypertension
Stress is considered as one of the factors associated with the development of many diseases, including the cardiovascular system. The history of studying stress as a risk factor for hypertension began in the first half of the 20th century and continued after the introduction of 24-hour blood pressure monitoring (ABPM) into clinical practice. Then it turned out that there is normotension, stable hypertension and latent hypertension: masked (when clinical BP is within the normal range, and arterial hypertension is recorded according to ABPM and/or self-monitoring of BP) and white coat hypertension (increased BP during a visit to the doctor when normal values of blood pressure according to ABPM or self-monitoring of BP). Currently, both variants of latent hypertension are classified as stress-induced arterial hypertension. Several models have been proposed for the study of stress, but two of them are more common in clinical studies: the Karasek model (based on an imbalance between job demands and job decision latitude) and the Siegrist model (based on an imbalance of effort and reward). There are only few studies in where attempts have been made to link the increase in BP with the parameters of stress response (for example, with hormonal levels) or genetic predisposition. The review discusses the most significant studies of stress-induced arterial hypertension published to date.
- 12 August 2022
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 94 (7) , 908-913
Open AccessStress-induced arterial hypertension
Stress is considered as one of the factors associated with the development of many diseases, including the cardiovascular system. The history of studying stress as a risk factor for hypertension began in the first half of the 20th century and continued after the introduction of 24-hour blood pressure monitoring (ABPM) into clinical practice. Then it turned out that there is normotension, stable hypertension and latent hypertension: masked (when clinical BP is within the normal range, and arterial hypertension is recorded according to ABPM and/or self-monitoring of BP) and white coat hypertension (increased BP during a visit to the doctor when normal values of blood pressure according to ABPM or self-monitoring of BP). Currently, both variants of latent hypertension are classified as stress-induced arterial hypertension. Several models have been proposed for the study of stress, but two of them are more common in clinical studies: the Karasek model (based on an imbalance between job demands and job decision latitude) and the Siegrist model (based on an imbalance of effort and reward). There are only few studies in where attempts have been made to link the increase in BP with the parameters of stress response (for example, with hormonal levels) or genetic predisposition. The review discusses the most significant studies of stress-induced arterial hypertension published to date.
- Open Access
- 28 October 2020
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 17 (3) , 7-34
Clinical practice guidelines on the diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease
One of the most common comorbid condition in people over 40 years old is: arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD). The frequency of AH in patients with COPD varies from 6.8 to 76.3%, in average 34.3%. COPD is detected in every fourth patient with hypertension in the age group of 2564 years. The current trend towards an increase in life expectancy and therefore growing pool of elder cohort, will lead to a higher number of patients with comorbid disorders. Diagnosis and treatment of AH and COPD are determined by current clinical recommendations for both nosologies, however, a number of mutual pathophysiological mechanisms lead to a more severe course of these diseases with frequent exacerbations. The choice of antihypertensive therapy in patients with AH in combination with COPD should be given to drugs that can provide an adequate decrease in blood pressure in hypoxic conditions, especially at night and early morning hours, that have prolonged effect or could be prescribed in the evening, and to those that dont worsen bronchial obstruction or exacerbate hypoxia. Patients with AH and COPD should be given recommendations on lifestyle changes, especially smoking cessation. As initial therapy calcium channel blockers, angiotensin receptor blockers or angiotensin-converting enzyme inhibitors should be considered. Calcium channel blockers/renin-angiotensin system blockers should be considered as the first line for combination therapy. Thiazide, thiazide-like diuretics orb1-selective adrenergic blockers could be prescribed in case of insufficient antihypertensive response or depending on different clinical scenarios. Bronchodilators are the baseline therapy in COPD with concomitant AH. According to modern concepts, prescription of combination therapy with different mechanisms of action is the most proven and justified approach, which leads to a decrease in the frequency of exacerbations of COPD and amelioration of the symptoms. The choice of bronchodilator in the case of a COPD and AH combination, should take into account the proven long-term safety regarding the risk of cardiovascular complications. Tiotropium bromide as the monotherapy, including as a liquid inhaler and aclidinium/formoterol, tiotropium/oladeterol as combination therapy showed cardiovascular safety in the long-term studies. The escalation of COPD therapy with the need of inhaled steroids requires careful monitoring of blood pressure and, possibly, a revision of antihypertensive treatment leading to its escalation as well. COPD has many phenotypes requiring different medications, eg.: roflumilast, theophylline, macrolides and mucoactive drugs, that could also require tighter blood pressure control on patients with COPD and AH.
- 28 October 2020
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 17 (3) , 7-34
Open AccessClinical practice guidelines on the diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease
One of the most common comorbid condition in people over 40 years old is: arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD). The frequency of AH in patients with COPD varies from 6.8 to 76.3%, in average 34.3%. COPD is detected in every fourth patient with hypertension in the age group of 2564 years. The current trend towards an increase in life expectancy and therefore growing pool of elder cohort, will lead to a higher number of patients with comorbid disorders. Diagnosis and treatment of AH and COPD are determined by current clinical recommendations for both nosologies, however, a number of mutual pathophysiological mechanisms lead to a more severe course of these diseases with frequent exacerbations. The choice of antihypertensive therapy in patients with AH in combination with COPD should be given to drugs that can provide an adequate decrease in blood pressure in hypoxic conditions, especially at night and early morning hours, that have prolonged effect or could be prescribed in the evening, and to those that dont worsen bronchial obstruction or exacerbate hypoxia. Patients with AH and COPD should be given recommendations on lifestyle changes, especially smoking cessation. As initial therapy calcium channel blockers, angiotensin receptor blockers or angiotensin-converting enzyme inhibitors should be considered. Calcium channel blockers/renin-angiotensin system blockers should be considered as the first line for combination therapy. Thiazide, thiazide-like diuretics orb1-selective adrenergic blockers could be prescribed in case of insufficient antihypertensive response or depending on different clinical scenarios. Bronchodilators are the baseline therapy in COPD with concomitant AH. According to modern concepts, prescription of combination therapy with different mechanisms of action is the most proven and justified approach, which leads to a decrease in the frequency of exacerbations of COPD and amelioration of the symptoms. The choice of bronchodilator in the case of a COPD and AH combination, should take into account the proven long-term safety regarding the risk of cardiovascular complications. Tiotropium bromide as the monotherapy, including as a liquid inhaler and aclidinium/formoterol, tiotropium/oladeterol as combination therapy showed cardiovascular safety in the long-term studies. The escalation of COPD therapy with the need of inhaled steroids requires careful monitoring of blood pressure and, possibly, a revision of antihypertensive treatment leading to its escalation as well. COPD has many phenotypes requiring different medications, eg.: roflumilast, theophylline, macrolides and mucoactive drugs, that could also require tighter blood pressure control on patients with COPD and AH.
- Open Access
- 27 March 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (3) , 78-83
Cardiovascular and chronic obstructive pulmonary diseases: pathophysiological processes and treatment tactics
Due to the global aging of the population, the deteriorating ecology and lifestyle changes, patients with isolated cardiovascular diseases (CVD) are becoming less common, and the portrait of a comorbid patient comes first in the structure of patients with CVD. Among a number of diseases complicating and concomitant with cardiovascular, a special place is occupied by chronic obstructive pulmonary disease (COPD). The prevalence of COPD among CVD patients can reach 60%. Many of the pathophysiological mechanisms underlying COPD can increase the risk of cardiovascular disease and vice versa. The most common cases of COPD are arterial hypertension, coronary heart disease, heart failure, and atrial fibrillation. Given the close relationship between COPD and CVD, it is clear that treatment for one condition can affect another. This review discusses current positions about the influence of both groups of diseases on each other, and also observes the effects of drug therapy of both diseases.
- 27 March 2020
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 92 (3) , 78-83
Open AccessCardiovascular and chronic obstructive pulmonary diseases: pathophysiological processes and treatment tactics
Due to the global aging of the population, the deteriorating ecology and lifestyle changes, patients with isolated cardiovascular diseases (CVD) are becoming less common, and the portrait of a comorbid patient comes first in the structure of patients with CVD. Among a number of diseases complicating and concomitant with cardiovascular, a special place is occupied by chronic obstructive pulmonary disease (COPD). The prevalence of COPD among CVD patients can reach 60%. Many of the pathophysiological mechanisms underlying COPD can increase the risk of cardiovascular disease and vice versa. The most common cases of COPD are arterial hypertension, coronary heart disease, heart failure, and atrial fibrillation. Given the close relationship between COPD and CVD, it is clear that treatment for one condition can affect another. This review discusses current positions about the influence of both groups of diseases on each other, and also observes the effects of drug therapy of both diseases.
- 1 March 2019
- Published by Pleiades Publishing Ltd in Russian Journal of Bioorganic Chemistry
- Vol. 45 (2) , 129-134
Specificity and Selectivity of a Modified Radioligand Method for Estimating the Binding Activity of β1 Adrenergic Receptors in Human T Lymphocytes
A radioligand-based method was proposed for quantifying the binding activity of β1-adrenergic receptors (ARs) on the surface of human T lymphocytes. Using the transfected HEK293 cell lines...
- 1 March 2019
- Published by Pleiades Publishing Ltd in Russian Journal of Bioorganic Chemistry
- Vol. 45 (2) , 129-134
Specificity and Selectivity of a Modified Radioligand Method for Estimating the Binding Activity of β1 Adrenergic Receptors in Human T Lymphocytes
A radioligand-based method was proposed for quantifying the binding activity of β1-adrenergic receptors (ARs) on the surface of human T lymphocytes. Using the transfected HEK293 cell lines...